There are maybe five or six moments in a company’s history where a single regulatory decision permanently shifts the competitive landscape. Philip Morris just had one of them.
A few weeks ago, the FDA issued Modified Risk Tobacco Product orders for 20 ZYN nicotine pouch variants. The ruling authorizes Swedish Match USA, Inc. (a Philip Morris International subsidiary) to market those specific ZYN products with the following claim: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” It is the first time any nicotine pouch has received this designation.
Read that again. No competitor holds this status. Not Altria. Not British American Tobacco. ZYN now carries FDA-authorized modified-risk language that can be used in marketing for those specific authorized products. That is not a minor regulatory footnote. That is a moat.
Philip Morris International (NYSE: PM) reports Q2 2026 results this morning. Analysts have been projecting approximately $10.56 billion in revenue and $2.04 in earnings per share, which would represent roughly 6.8% EPS growth from the year-ago period. The company has beaten EPS estimates in each of its last four quarters, with a trailing four-quarter average surprise of about 4.9%.
The Transformation Is Already Happening
In Q1 2026, smoke-free products accounted for 43% of Philip Morris’s total net revenues. International smoke-free net revenues grew 24.7% year over year, with gross profit in that segment up 28.6%. Adjusted diluted EPS for the quarter climbed 16% to $1.96.
The business is moving fast. IQOS heat-not-burn products are gaining share across markets. ZYN international volumes are growing. The company launched ZYN ULTRA in the U.S. and continues to prepare for a broader IQOS commercialization in the U.S. Full-year 2026 adjusted EPS guidance is set at $8.36 to $8.51, which implies 10.9% to 12.9% growth over 2025 levels.
The smoke-free pivot that looked aspirational a few years ago now looks like the majority of the business in a few more.
Here is the part the market may be underweighting. The ZYN MRTP authorization is not just a branding win. It differentiates ZYN at the point of sale in a way that is legally protected and backed by FDA’s scientific review for those specific products and that specific claim. Competitors cannot make the same claim without their own MRTP orders. Retailers notice shelf placement differently when one product carries FDA-authorized risk-modification language and the others do not. That has pricing implications and long-term share implications that Q2 will begin to quantify.
The U.S. Headwind Is Real, But It Is Normalizing
The Q1 U.S. segment was a clear weak spot. Net revenues fell 30.8%, and ZYN shipment volumes dropped 23.5%, as distributors worked down elevated inventories. The company attributed the decline to normalization after an aggressive stocking period, not to demand destruction. Consumer offtake, the actual consumption measure, grew roughly 10% even while shipments fell.
That distinction matters. Shipment volumes are a trade-level figure. Consumer offtake is demand. The inventory cycle washout appears to be running its course, and Q2 will be the first quarter where management can address the ZYN trajectory under the new modified-risk marketing framework.
Analysts have submitted more downward than upward EPS revisions over the past 90 days, which creates a relatively modest bar for a beat. The trailing four-quarter surprise history suggests the company has a habit of exceeding that bar.
The Competitive Picture
Think about what the ZYN MRTP ruling does to the competitive positioning over time. Other nicotine pouch brands can compete on price, flavor, and distribution. They cannot compete on FDA-authorized reduced-risk claims unless they go through the same multiyear scientific submission process and win approval. That process is slow, expensive, and uncertain. ZYN effectively has a regulatory head start measured in years, not months.
Philip Morris completed its acquisition of Swedish Match, ZYN’s manufacturer, and has been building the brand as a cornerstone of its smoke-free strategy alongside IQOS. The company now has multiple smoke-free pillars operating simultaneously across different product categories and geographies. That diversification within the smoke-free portfolio is something the company’s combustibles-era competitors do not have.
The stock is up roughly 13% year to date heading into today’s print. The average analyst price target sits near $194, which implies limited upside from current levels at face value. But price targets rarely capture inflection points in competitive positioning. Today’s call is the first opportunity for management to frame the commercial implications of the MRTP ruling in detail, including ZYN’s volume trajectory, market-share dynamics, and how modified-risk marketing will actually be deployed across channels.
The smoke-free transformation at Philip Morris has been building for years. The FDA just handed it something no competitor has. Today is when investors find out how the company plans to use it.
